Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | STS | P08842 | 4/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.35 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.35 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18630264 | 0.98 | CYP2C19 (0.53) | NAAACYP2C19HTTCYP19A1EPHX1 | |
| SCHEMBL75532 | 0.98 | CYP2C19 (0.53) | NAAACYP2C19HTTCYP19A1EPHX1 | |
| SCHEMBL16439889 | 0.98 | NAAA (0.48) | NAAACYP2C19HTTCYP19A1EPHX1 | |
| SCHEMBL23813855 | 0.98 | CYP2C19 (0.53) | NAAACYP2C19HTTCYP19A1EPHX1 | |
| Hydrochloric Acid SCHEMBL7309629 | 0.98 | NAAA (0.48) | NAAACYP2C19HTTCYP19A1EPHX1 | |
| SCHEMBL23813782 | 0.98 | CYP2C19 (0.53) | NAAACYP2C19HTTCYP19A1EPHX1 | |
| SCHEMBL18186688 | 0.98 | CYP2C19 (0.53) | NAAACYP2C19HTTCYP19A1EPHX1 | |
| Hydrochloric Acid SCHEMBL7309555 | 0.96 | CYP2C19 (0.52) | NAAACYP2C19HTTCYP19A1EPHX1 | |
| SCHEMBL16439874 | 0.96 | CYP2C19 (0.52) | NAAACYP2C19HTTCYP19A1EPHX1 | |
| SCHEMBL16439937 | 0.96 | CYP2C19 (0.52) | NAAACYP2C19HTTCYP19A1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 523 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340595-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TRANSFERRIN RECEPTOR 1 (TfR1) | BICYCLETX LTD (GB) | 2025-11-06 | — | — | US | claimed |
| US-20240391959-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TRANSFERRIN RECEPTOR 1 (TfR1) | BICYCLETX LIMITED (GB) | 2024-11-28 | — | — | US | claimed |
| US-20240382605-A1 | CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2024-11-21 | — | — | US | claimed |
| EP-4408433-A1 | CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | Ionis Pharmaceuticals, Inc. (US) | 2024-08-07 | — | — | EP | claimed |
| US-11970555-B2 | Bicyclic peptide ligands specific for transferrin receptor 1 (TfR1) | BICYCLETX LIMITED (GB) | 2024-04-30 | — | — | US | claimed |
| EP-4244235-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TRANSFERRIN RECEPTOR 1 (TFR1) | BicycleTX Limited (GB) | 2023-09-20 | — | — | EP | claimed |
| WO-2023056388-A1 | CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2023-04-06 | — | — | WO | claimed |
| US-20220194988-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TRANSFERRIN RECEPTOR 1 (TfR1) | BICYCLETX LIMITED (GB) | 2022-06-23 | — | — | US | claimed |
| WO-2022101633-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TRANSFERRIN RECEPTOR 1 (TfR1) | BICYCLETX LIMITED (GB) | 2022-05-19 | — | — | WO | claimed |
| CN-103930437-A | Potent and selective inhibitors of Nav1.3 and Nav1.7 | AMGEN INC | 2014-07-16 | — | — | CN | claimed |
| CN-103370331-A | Amino statin derivatives for the treatment of arthrosis | MERCK PATENT GMBH | 2013-10-23 | — | — | CN | claimed |
| EP-0950046-B1 | 3,4-DISUBSTITUTED AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE REGULATORS | NAEJA PHARMACEUTICAL INC (CA) | 2002-04-10 | — | — | EP | claimed |
| EP-0961779-A1 | SUBSTITUTED AMINO BICYCLIC-$g(b)-LACTAM PENAM AND CEPHAM DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS | SYNPHAR LABORATORIES INC. (CA) | 1999-12-08 | — | — | EP | claimed |
| EP-0950046-A1 | 3,4-DISUBSTITUTED AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE REGULATORS | SYNPHAR LABORATORIES INC. (CA) | 1999-10-20 | — | — | EP | claimed |
| WO-1998032766-A1 | SUBSTITUTED AMINO BICYCLIC-β-LACTAM PENAM AND CEPHAM DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS | SYNPHAR LABORATORIES INC. (US) | 1998-07-30 | — | — | WO | claimed |
| WO-1998012176-A1 | 3,4-DISUBSTITUTED AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE REGULATORS | SYNPHAR LABORATORIES INC. (US) | 1998-03-26 | — | — | WO | claimed |
| CN-1148393-A | Bradykinin antagonist peptides incorporating N-substituted glycines | CORTECH INC (US) | 1997-04-23 | — | — | CN | claimed |
| US-12624358-B2 | Compounds and methods for reducing PLN expression | IONIS PHARMACEUTICALS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| WO-1987002669-A1 | PHOSPHINYLALKANOYL IMINO ACIDS | SCHERING CORPORATION (US) | 1987-05-07 | — | — | WO | disclosed |
| CN-86105218-A | The preparation method of antiparasitic agents | — | 1987-03-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11970555-B2 | Bicyclic peptide ligands specific for transferrin receptor 1 (TfR1) | TFRC, FTH1, SLC40A1 | NAAA 4682/4885CYP2C19 3736/4885HTT 408/4885 |
| US-20240391959-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TRANSFERRIN RECEPTOR 1 (TfR1) | TFRC, FTH1, SLC40A1 | NAAA 4682/4885CYP2C19 3736/4885HTT 408/4885 |
| US-20250340595-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TRANSFERRIN RECEPTOR 1 (TfR1) | TFRC, FTH1, SLC40A1 | NAAA 4682/4885CYP2C19 3736/4885HTT 408/4885 |
| US-20220194988-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TRANSFERRIN RECEPTOR 1 (TfR1) | TFRC, FTH1, SLC40A1 | NAAA 4682/4885CYP2C19 3736/4885HTT 408/4885 |
| US-12624358-B2 | Compounds and methods for reducing PLN expression | PHAX, ACTN1, ATP2A1 | NAAA 3004/4885CYP2C19 4855/4885HTT 2731/4885 |
| US-20240382605-A1 | CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | DCLRE1B, PLK1, PAICS | NAAA 4720/4885CYP2C19 4756/4885HTT 2711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.